LFB Biomanufacturing

LFB Biomanufacturing Contract Manufacturing & Development (CDMO) Profile

If you are looking for a human-sized structure to accompany you in the development of your biologics, antibodies or proteins with an End-to-End offer, up to the manufacturing of clinical or commercial batches;we are a French CDMO belonging to LFB Group, with scalable capacities that will adapt to the different clinical phases of your project.

At LFB Biomanufacturing we understand your manufacturing requirements because we have 25 years of experience in development and manufacturing of therapeutic proteins, a solid track record, including ANSM and FDA certifications. Our process and analytical development teams will provide you with technical and regulatory expertise, in fast-track development on a technological platform, or on a custom basis, according to your needs. We can provide Drug conjugation with preferred subcontractors.

Our current customers appreciate our agility, our reliability and qualify our services as very competitive.

CDMO Services:
Biologics Drug Substance Manufacturing (API); Drug Product Formulation (FDF); Research & Development; Regulatory Services; Analytical Development Liquids Analytical Development; Cell Line Development; Formulation Development; ICH Stability Testing; Process Development Antibodies; Antibody-drug conjugate (ADC); Fusion Proteins; Recombinants + other Proteins

Year Founded: 1994

Head Office: Les Ulis, France

Number of Facilities: 1

Facility locations: Europe

Website: Visit the LFB Biomanufacturing website

Linkedin: Connect on Linkedin

Current Capacity: Authorized for the manufacturing of Investigational medicinal products LFB BMG is offering to its CUSTOMERs a comprehensive set of CDMO services.

• It can offer mammalian cell line development (CLD) capabilities with most common recombinant mammalian cell lines such as CHO. LFB BMG can provide the access to CHO-DG44 through a preferred subcontracted CLD with CellCa/Sartorius. Moreover, LFB BMG can propose the EMABling® platform using the proprietary YB2/0-E cell line to produce recombinant monoclonal antibodies having an enhanced antibody-dependent cellular cytotoxicity (ADCC) activity due to a specific glycosylation pattern.

• Upstream (USP) and downstream process (DSP) development and optimizations are executed in state-of-the-art facilities using both “platform-type” and customized approaches. LFB BMG’s technological options are mainly focused on disposable equipment such as Ambr® system or Single-Use Bioreactors.

• Customized GMP manufacturing for clinical trial and/or for commercial supply, using the evolving approach of its large scale GMP manufacturing facility;The GMP manufacturing offer is currently from 200 to 2000 liters in single use bioreactor.